IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

WHOLE EYE TRANSPLANTATION BY USING THE INDUCED PLURIPOTENT STEM CELLS TO CREATE GANGLION CELLS

Sankar Mahesh M,Vanmathi B
Student ,Assistant Professor
B.E.Bio Medical
PARK College Of Engineering And Technology,Coimbatore,India

ABSTRACT :

Blindness is a significant global issue with no cure. Whole-eye transplantation (WET) is a promising potential treatment, involving transplanting a viable eye from a deceased(The Patient Who Affected by brain Dead OR Something Else Like The Brain Dead Stage) donor to a blind person's orbital socket. Animal models have shown varying levels of success in restoring vision, particularly in cold-blooded vertebrates. However, further research is needed to improve understanding of nerve regeneration, immunosuppression, and surgical techniques for WET.

INTRODUCTION :

Whole eye transplantation is a potential alternative for patients with irreversible vision loss caused by severe retinal ganglion cell (RGC) axon damage. However, previous attempts at total eye transplantation have failed due to the inability to ensure adequate circulation of blood to the transplanted eye, the difficulty of optic nerve regeneration with restoration of topographic organization, and immune rejection of foreign tissue. To overcome these impediments, researchers have turned to the use of induced pluripotent stem cells (iPSCs), which have the ability to differentiate into various cell types, including RGCs. The use of iPSCs in combination with a suitable animal model, such as rabbits, could potentially lead to the development of a successful whole eye transplantation procedure. The rabbit's unique anatomical characteristics, extensive knowledge of rabbit research in ophthalmology, and the possibility of reproducibility make it an ideal subject to be used as a model in ophthalmic research. However, further research is needed to determine the best method for optic nerve neurorrhaphy and to establish reproductible animal models.

LITERATURE REVIEW :

Retinal degenerative diseases are the leading cause of irreversible blindness worldwide. Recent advances in stem cell technology have shown promising results in the field of regenerative medicine for the treatment of retinal degenerative diseases. One such approach is the use of induced pluripotent stem cells (iPSCs) for generating retinal ganglion cells (RGCs), which are the primary neurons responsible for transmitting visual information from the retina to the brain.Numerous studies have reported successful generation of RGCs from iPSCs in vitro, which has led to the development of pre-clinical models for the transplantation of iPSC-derived RGCs. Several preclinical studies have demonstrated the feasibility and safety of iPSC-derived RGC transplantation in animal models of retinal degenerative diseases.In a study conducted by Mandai et al., autologous iPSC-derived RGCs were transplanted into the eyes of two patients with advanced retinal degeneration. The results of this study showed that the transplantation of iPSC-derived RGCs was well-tolerated and did not cause any adverse effects. The patients showed some improvement in visual function, which was confirmed by electroretinography.In another study conducted by Tucker et al., iPSC-derived RGCs were transplanted into the eyes of rats with optic nerve injury. The results of this study showed that the transplantation of iPSC-derived RGCs led to the partial restoration of visual function in the rats.Moreover, several preclinical studies have reported that the transplantation of iPSC-derived RGCs has the potential to rescue photoreceptors and preserve visual function in animal models of retinal degenerative diseases. However, further studies are required to assess the long-term safety and efficacy of iPSC-derived RGC transplantation in humans.

In conclusion, The use of iPSCs for generating RGCs holds great promise for the treatment of retinal degenerative diseases. Preclinical studies have demonstrated the feasibility and safety of iPSC-derived RGC transplantation in animal models, and early clinical studies have shown some improvement in visual function. However, further studies are required to optimize the protocols for generating RGCs from iPSCs and to evaluate the long-term safety and efficacy of iPSC-derived RGC transplantation in humans.

METHADOLOGY:

There are several type of stem cells are available in human body but in Whole Eye Transplantation there is only iPSC (Induced Pluripotent Stem Cells) Are used because of the Importance and Usage of iPSCs:

iPSCs have gained considerable attention in the field of regenerative medicine due to their potential to differentiate into any cell type in the body. Moreover, iPSCs can be generated from the patient's own cells, thus minimizing the risk of immune rejection. In the case of eye transplantation, iPSCs can be differentiated into retinal ganglion cells, photoreceptor cells, and other retinal cells, which can be used for transplantation. iPSCs can also be used for disease modeling and drug discovery, which can aid in developing new therapies for retinal diseases. Therefore, iPSCs have great potential for the development of effective therapies for eye diseases.

The Varios Steps Followed To Generate The Retinal Ganglion Cells,Photoreceptor Cells And Other Retinal Cells From The Induced Pluripotent Stem Cells:

iPSC generation:
First, iPSCs are generated by reprogramming adult cells such as skin cells, into a pluripotent stem cell state. This is achieved by introducing specific genes into the cells, which alters their gene expression profile and allows them to develop into any type of cell in the body.

Differentiation into neural progenitor cells:
The iPSCs are then differentiated into neural progenitor cells (NPCs) through the use of specific growth factors and signaling molecules. These NPCs have the potential to develop into any type of neuron, including retinal ganglion cells and photoreceptor cells.

Induction of retinal fate:
The NPCs are further treated with a combination of signaling molecules to induce their differentiation into retinal cells. This involves exposing the cells to specific factors that promote the development of retinal cells, such as Wnt and Nodal signaling molecules.

Maturation of retinal cells:
Once the retinal cells have been induced, they are further matured through the use of specific growth factors and environmental cues. This allows the cells to develop the complex structures and functions required for proper vision.

RESULTS :

The results of whole eye transplantation using induced pluripotent stem cells (iPSCs) to generate retinal ganglion cells and other retinal cells have shown promising outcomes. Animal studies have demonstrated successful integration of transplanted cells into the host retina, with the transplanted cells forming functional connections with host cells. Additionally, functional improvements have been observed in visual behavior tests in animal models, suggesting the potential for restoration of vision in humans with retinal degenerative diseases. However, further research is needed to optimize the transplantation procedure and ensure long-term safety and efficacy of the therapy in humans.

DISSCUSSION :

The possibility of whole eye transplantation using induced pluripotent stem cells (iPSCs) to create ganglion cells has opened up a new avenue in the field of regenerative medicine. The use of iPSCs for this purpose has several advantages over other stem cell types. First, iPSCs can be generated from the patient's own cells, reducing the risk of immune rejection. Second, iPSCs have the ability to differentiate into different types of cells, including retinal ganglion cells.

The success of generating retinal ganglion cells from iPSCs has been demonstrated in several studies. For example, a study conducted by Mandai et al. (2017) showed that iPSC-derived retinal ganglion cells were able to integrate into the host retina and form functional synapses. Another study by Tucker et al. (2017) demonstrated the successful transplantation of iPSC-derived retinal ganglion cells into the eyes of blind rats, resulting in improved visual function.

Despite these promising results, there are still several challenges that need to be addressed before whole eye transplantation using iPSCs can become a viable treatment option for patients with vision loss. One major challenge is the risk of tumor formation, as iPSCs have the potential to form teratomas when transplanted in vivo. Additionally, more research is needed to optimize the differentiation protocols for iPSCs to generate fully functional retinal ganglion cells.

In conclusion, the use of iPSCs to generate retinal ganglion cells for whole eye transplantation has the potential to revolutionize the field of regenerative medicine. Although there are still challenges that need to be addressed, the promising results from preclinical studies suggest that iPSC-based whole eye transplantation could become a viable treatment option for patients with vision loss in the future.

CONCLUSION :

The use of induced pluripotent stem cells (iPSCs) has shown promising potential for generating retinal ganglion cells and other retinal cells, paving the way for the possibility of whole eye transplantation. The success of the transplantation depends on several factors such as the survival and integration of the transplanted cells, immune rejection, and functional outcomes. However, the use of iPSCs provides a valuable tool for personalized medicine and individualized treatment for patients with vision loss.The process of generating retinal ganglion cells from iPSCs involves various steps such as induction of iPSCs into retinal progenitor cells, differentiation into retinal ganglion cells, and maturation into functional cells. While several other stem cell regeneration methods are available, iPSCs offer unique advantages such as their ability to be derived from a patient's own cells, reducing the risk of immune rejection and increasing the chances of successful transplantation.Future research and clinical trials will provide further insight into the safety and efficacy of whole eye transplantation using iPSC-generated retinal cells. However, the potential benefits of this approach in restoring vision and improving

the quality of life for patients cannot be overlooked. Overall, the use of iPSCs for the generation of retinal cells and whole eye transplantation is a promising avenue for the treatment of vision loss and blindness.

REFERENCES :

1. Ellenberg D, Shi J, Jain S, Chang JH, Brady S, Melhem E et al. Impediments to eye transplantation: ocular viability following optic nerve transection or enucleation. Br J Ophthalmol 2009; 93: 1134–1140.

2. Scientists urged to hold firm to eye transplant goal. JAMA 1978; 240(12)1227.

3. Carty MJ, Bueno EM, Soleymani Lehmann L, Pomahac B. A position paper in support of face transplantation in the blind. Plast Reconstr Surg 2012; 130: 319–324.

4. Stone LS. Heteroplastic transplantation of the eyes between the larvae of two species of Amblystoma. J Exp Zool 1930; 55: 193–261.

5. Stone LS, Cole HS. Grafted eyes of young and old adult salamanders (amblystoma punctatum showing return of vision. Yale J Biol Med 1943; 15: 735–755.

6. Stone L, Ussher N, Beers D. Reimplantation and transplantation of larval eyes into the salamander Amblystoma punctum. J Exp Zool 1937; 77: 13–47.

7. Stone L, Zaur L. Reimplantation and transplantation of adult eyes in the salamander (triturus viridescens with return of vision. J Exp Zool 1940; 85: 243–269.

8. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokhare l GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844-51.

9. Flaxman SR, Bourne RR, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment
10. 1990-2020: a systematic review and meta-analysis. Lancet Glob Health.2017;5(12):e1221-e1234.

11. Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol. 2014;98(5):629-38.

12. Ellenberg D, Shi J, Jain S, Chang JH, Ripps H, Brady S, et al. Impediments to eye transplantation: ocular viability following optic-nerve transection or enucleation. Br J Ophthalmol. 2009;93(9):1134-40.

13. Scientists urged to hold firm to eye transplant goal. JAMA. 1978;240(12):1227.